Sodium 2,4-dichloro-6-((3,5-dichloro-2-hydroxyphenyl)thio)phenolate | 20284-98-4

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: Sodium 2,4-dichloro-6-((3,5-dichloro-2-hydroxyphenyl)thio)phenolate
• 英文别名: sodium;2,4-dichloro-6-(3,5-dichloro-2-hydroxyphenyl)sulfanylphenolate
• CAS: 20284-98-4
• 化学式: C12H5Cl4NaO2S
• 分子量: 378.0
• InChiKey: GBQJZSAUYCFSGW-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.23
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  68.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
  申请人：UNIV ALABAMA

  公开号：WO2010078300A1

  公开（公告）日：2010-07-08

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.

  本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物，以及其使用方法。进一步揭示了包括液态离子对的物质组合物，单独或溶解后使用；以及离子液体的“溶剂化”组合物，例如“水合”的组合物及其用途。
• [EN] LIPOSOMAL PARTICLES COMPRISING BIOLOGICAL MOLECULES AND USES THEREOF<br/>[FR] PARTICULES LIPOSOMALES COMPRENANT DES MOLÉCULES BIOLOGIQUES ET UTILISATIONS ASSOCIÉES
  申请人：UNIV MICHIGAN

  公开号：WO2016123365A1

  公开（公告）日：2016-08-04

  Provided herein are liposomal particles. In particular, provided herein are liposomal particles comprising molecules (e.g., antigens or drugs) and uses thereof (e.g., as a vaccine (e.g., intranasal vaccine) or drug delivery system). For example, in some embodiments, the present disclosure provides a composition comprising: a molecule encapsulated in a liposome comprising one or more cationic lipids and hyaluronic acid (HA). In some embodiments, the one or more lipids are DOTAP and/or DOPE. In some embodiments, the HA is thiolated. In some embodiments, the thiolated HA is conjugated to thiolated PEG.

  本文提供了脂质体颗粒。特别地，本文提供了包含分子（例如抗原或药物）的脂质体颗粒及其用途（例如作为疫苗（例如鼻内疫苗）或药物输送系统）。例如，在某些实施例中，本公开提供了一个组合物，包括：分子封装在一个脂质体中，该脂质体包括一个或多个阳离子脂质和透明质酸（HA）。在某些实施例中，一个或多个脂质是DOTAP和/或DOPE。在某些实施例中，HA是硫酸化的。在某些实施例中，硫酸化的HA与硫酸化的PEG结合。
• Fatty alcohol drug conjugates
  申请人：——

  公开号：US20020177609A1

  公开（公告）日：2002-11-28

  The invention provides conjugates of fatty alcohols and pharmaceutical agents useful in treating cancer, viruses, psychiatric disorders. Compositions, pharmaceutical preparations, and methods of preparation of the fatty alcohols-pharmaceutical agent conjugates are provided.

  本发明提供了脂肪醇和药物的结合物，可用于治疗癌症、病毒和精神障碍。本发明还提供了脂肪醇-药物结合物的组成、制药制剂和制备方法。